The CONFIRM trial is a double blind randomised phase III trial which is investigating the use of Nivolumab versus placebo in patients with relapsed mesothelioma. CONFIRM is now closed and no longer recruiting.
The CONFIRM trial is a double blind randomised phase III trial which is investigating the use of Nivolumab versus placebo in patients with relapsed mesothelioma. CONFIRM is now closed and no longer recruiting.